Anti-chi3l1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/ nonalcoholic steatonhepatitis and subsequent complications
AssigneeRhode Island Hospital
InventorsJack R. Wands, Rolf I. Carlson
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to antibodies that bind human chitinase-3-like protein 1 (CHI3L1) and uses thereof. In aspects, the antibodies are useful in compositions and methods for detecting and/or treating nonalcoholic steatohepatitis (NAFLD) or nonalcoholic fatty liver disease (NASH) in a subject, as well as subsequent complications of untreated progression in the liver of a subject, such as liver cirrhosis and/or a hepatocellular carcinoma.
Claims9
An antibody that binds to human CHI3L1 comprising a light chain and a heavy chain, wherein the light chain comprises a light chain variable region (LCVR) and the heavy chain comprises a heavy chain variable region (HCVR), wherein the LCVR comprises complementarity determining regions LCDR1, LCDR2, and LCDR3, and the HCVR comprises complementarity determining regions HCDR1, HCDR2, and HCDR3, wherein LCDR1 consists of amino acid sequence SEQ ID NO:6, LCDR2 consists of amino acid sequence SEQ ID NO:7, LCDR3 consists of amino acid sequence SEQ ID NO:8, HCDR1 consists of amino acid sequence SEQ ID NO:3, HCDR2 consists of amino acid sequence SEQ ID NO:4, and HCDR3 consists of amino acid sequence SEQ ID NO:5.
A DNA molecule comprising a polynucleotide sequence encoding a light chain polypeptide having the amino acid sequence SEQ ID NO:
- 12.
A DNA molecule comprising a polynucleotide sequence encoding a heavy chain polypeptide having the amino acid sequence SEQ ID NO:
- 11.
7-9. (canceled)
11-41. (canceled)
Dependencies are inferred from the claim text.